Toxic epidermal necrolysis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Toxic Epidermal Necrolysis – Comprehensive Medical Guide

Overview

Toxic epidermal necrolysis (TEN) is an acute, life‑threatening skin reaction characterized by widespread keratinocyte death that leads to detachment of the epidermis over large body surfaces. It is considered the most severe form of the spectrum of severe cutaneous adverse reactions (SCARs), which also includes Stevens‑Johnson syndrome (SJS). While SJS involves <10 % of body surface area (BSA), TEN involves >30 % BSA, and an “SJS/TEN overlap” occupies 10‑30 %.

Who it affects: TEN can occur at any age but is most common in adults aged 30‑50 years. Women are slightly more often affected than men (≈ 1.3:1). The condition is rare, with an estimated incidence of 0.4–1.9 cases per million person‑years worldwide.[1][2]

Because the disease destroys the protective skin barrier, patients are at high risk for infection, fluid loss, and organ dysfunction, making early recognition and treatment critical.

Symptoms

Symptoms usually begin 1–3 weeks after exposure to a triggering drug or, less commonly, an infection. The clinical picture evolves rapidly over 48–72 hours.

Early (Prodromal) Phase

  • Fever ≥ 38 °C (100.4 °F) – often the first sign.
  • Flu‑like symptoms: sore throat, malaise, headache, cough.
  • Conjunctival redness or tearing.
  • Oral discomfort, sore throat, or burning sensation.

Cutaneous Phase

  • Macules and maculopapules: Pink or erythematous spots that may coalesce.
  • Targetoid lesions: Similar to those seen in erythema multiforme, but less distinct.
  • Blister formation: Tense vesicles that quickly rupture.
  • Full‑thickness epidermal necrosis: The skin sloughs off like a sheet; the detached areas are tender and often positive for the “Nikolsky sign” (gentle lateral pressure causes the skin to shear off).
  • Distribution: In TEN, >30 % of BSA is involved, commonly affecting the trunk, face, and extremities. The palms, soles, and mucous membranes are frequently involved.

Mucosal Involvement

  • Oral cavity – painful erosions, difficulty swallowing.
  • Ocular – conjunctivitis, corneal ulceration, potential blindness.
  • Genitourinary – vulvar or penile erosions, dysuria.
  • Respiratory – laryngeal edema, hoarseness.

Systemic Manifestations

  • Hypotension and tachycardia due to fluid loss.
  • Acute kidney injury.
  • Liver enzyme elevation.
  • Electrolyte disturbances (e.g., hyponatremia).

Causes and Risk Factors

Over 80 % of TEN cases are drug‑induced. The reaction is thought to be a type IV hypersensitivity mediated by cytotoxic T‑cells and natural killer cells that release granulysin, perforin, and granzyme B, leading to keratinocyte apoptosis.

Common Triggers

  • Antiepileptics: carbamazepine, lamotrigine, phenytoin, phenobarbital.
  • Antibiotics: sulfonamides, beta‑lactams (especially amoxicillin‑clavulanate), quinolones.
  • Allopurinol – one of the most frequent causes.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs), especially oxicam derivatives.
  • Antiretrovirals (e.g., nevirapine).
  • Rarely, vaccines, contrast agents, or herbal supplements.

Non‑Drug Triggers

  • Infections: Mycoplasma pneumoniae, herpes simplex virus, hepatitis A/B/C.
  • Malignancies: especially lymphomas.

Risk Factors

  • Genetic predisposition: HLA‑B*1502 in Han Chinese and Southeast Asian populations markedly increases risk with carbamazepine.[3]
  • Previous exposure to the same drug class.
  • Immunocompromised state (e.g., HIV infection, organ transplant).
  • Older age and female sex (modest increase).
  • Poly‑pharmacy – simultaneous use of several high‑risk drugs.

Diagnosis

Diagnosing TEN is primarily clinical, but laboratory and histologic studies support severity assessment and rule out mimickers (e.g., staphylococcal scalded skin syndrome, bullous pemphigoid). Prompt recognition within the first 72 hours dramatically improves outcomes.

Clinical Evaluation

  • Detailed history of medication exposure within the past 4 weeks.
  • Physical exam estimating % BSA involvement (rule of 9s).
  • Assessment of mucosal surfaces.

Laboratory Tests

  • Complete blood count – may show leukocytosis or eosinophilia.
  • Comprehensive metabolic panel – monitor renal and hepatic function.
  • Inflammatory markers: CRP, ESR.
  • Blood cultures if fever is present.

Skin Biopsy

Incisional biopsy (4 mm) from an active edge is gold standard. Histopathology shows full‑thickness epidermal necrosis with minimal dermal inflammation. Direct immunofluorescence helps exclude autoimmune blistering diseases.

Scoring Systems

  • SCORTEN: A 7‑point severity score (age > 40 y, heart rate > 120 bpm, cancer, >10 % BSA detachment, serum urea > 10 mmol/L, glucose > 14 mmol/L, bicarbonate < 20 mmol/L). Each positive variable adds 1 point; scores ≥ 3 predict mortality > 30 %.[4]

Treatment Options

TEN requires care in an intensive care unit (ICU) or specialized burn unit because the management parallels severe burns.

Immediate Measures

  • Discontinue the offending drug immediately – no “wash‑out” period.
  • Transfer to a center with experienced burn/critical care facilities.
  • Implement strict infection‑control precautions.

Supportive Care (Cornerstone)

  • Fluid and electrolyte replacement – calculate needs similar to burn resuscitation (e.g., Parkland formula).
  • Temperature regulation – maintain a neutral environment; use blankets or cooling devices as needed.
  • Pain control – intravenous opioids are often required.
  • Nutritional support – high‑protein, enteral feeding (nasogastric or PEG) to promote wound healing.
  • Wound care – non‑adhesive dressings, povidone‑iodine or silver‑impregnated dressings; avoid debridement unless necrotic tissue threatens infection.
  • Eye care – lubricating eye drops, ophthalmology consultation, prophylactic topical antibiotics.

Pharmacologic Therapies

Evidence is mixed; choices depend on institutional experience and patient condition.

  • Corticosteroids – High‑dose IV methylprednisolone (1–2 mg/kg/day) for 3‑5 days may halt progression, but increased infection risk limits use. Recent meta‑analyses suggest no survival benefit when used alone.[5]
  • Intravenous Immunoglobulin (IVIG) – Doses 2 g/kg over 2‑3 days; proposed to block Fas‑mediated keratinocyte apoptosis. Some cohort studies show reduced mortality, especially when administered early, but randomized data are inconclusive.[6]
  • Cyclosporine – 3‑5 mg/kg/day IV or oral; inhibits T‑cell activation. Several observational studies report lower SCORTEN scores and improved survival.[7]
  • TNF‑α inhibitors (e.g., etanercept) – Case series suggest rapid disease halting and shorter hospital stay; still investigational.
  • Plasmapheresis – May remove circulating cytokines and drug metabolites; reserved for refractory cases.

Procedural Interventions

  • Early ophthalmology evaluation and possible amniotic membrane transplantation for severe ocular involvement.
  • Skin grafting is seldom needed because re‑epithelialization occurs naturally; grafts are considered only for extensive, slow‑healing areas.

Rehabilitation

  • Physical therapy to maintain range of motion.
  • Scar management – silicone sheets, pressure garments.
  • Psychological support – PTSD, depression are common after severe SCARs.

Living with Toxic Epidermal Necrolysis

Survivors often face long‑term sequelae. Below are practical tips for daily life after discharge.

Skin Care

  • Moisturize with fragrance‑free emollients at least twice daily.
  • Avoid hot water, harsh soaps, and abrasive clothing.
  • Use sunscreen (SPF 30+) to protect hypo‑pigmented areas.

Eye Health

  • Continue lubricating drops as prescribed.
  • Attend regular ophthalmology follow‑ups; early detection of symblepharon or cataract is essential.

Oral and Genitourinary Care

  • Maintain oral hygiene with a soft‑bristled toothbrush and alcohol‑free mouthwash.
  • Stay hydrated; use vaginal moisturizers if dryness persists.

Medication Management

  • Carry an up‑to‑date drug allergy card listing the offending agents.
  • Inform every healthcare provider of the TEN history before prescribing new meds.
  • Consider pharmacogenetic testing (e.g., HLA‑B*1502) before re‑exposure to high‑risk drugs.

Psychosocial Support

  • Join support groups (e.g., SJS/TEN Foundation) to share experiences.
  • Seek counseling if anxiety, depression, or post‑traumatic stress symptoms arise.

Follow‑up Schedule

  • First month: weekly wound check and labs.
  • Months 2‑6: monthly dermatology and ophthalmology visits.
  • Beyond 6 months: assess for chronic skin changes, ocular complications, and quality‑of‑life issues.

Prevention

Because most cases are drug‑related, primary prevention focuses on medication safety.

  • Medication reconciliation at every encounter; review all prescriptions, over‑the‑counter drugs, and supplements.
  • Pharmacogenomic screening for high‑risk populations (e.g., HLA‑B*1502 before carbamazepine in Asian patients).
  • Electronic prescribing alerts that flag known high‑risk drugs for patients with a prior TEN episode.
  • Patient education on early warning signs (fever, painful rash) and the importance of reporting them immediately.

Complications

If not identified and managed promptly, TEN can lead to life‑threatening and chronic problems.

  • Infection – sepsis is the leading cause of mortality (up to 30 % of deaths). Common pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, and Candida spp.
  • Fluid‑electrolyte imbalance – hypovolemia, hyponatremia, hyperkalemia.
  • Acute organ dysfunction – acute kidney injury, hepatic failure, myocardial depression.
  • Long‑term scarring – hypertrophic or atrophic scars, contractures.
  • Ocular sequelae – chronic dry eye, symblepharon, cataracts, blindness (up to 10 % of survivors).
  • Oral complications – persistent dysphagia, xerostomia.
  • Psychological impact – depression, anxiety, PTSD in up to 50 % of patients.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following:
  • Fever higher than 38 °C (100.4 °F) combined with a painful, spreading rash.
  • Blistering or skin that peels off, especially if it involves >10 % of your body.
  • Severe eye pain, redness, or difficulty opening your eyes.
  • Swelling of the lips, mouth, or throat that makes swallowing or breathing hard.
  • Rapid heartbeat, dizziness, or fainting (signs of shock).
  • Sudden drop in urine output or dark-colored urine.

Early medical attention dramatically improves survival and reduces complications.

References

  1. Rzany B, et al. “Incidence of Stevens‑Johnson syndrome and toxic epidermal necrolysis in Europe.” *British Journal of Dermatology*, 2008.
  2. Mockenhaupt M, et al. “Epidemiology of Stevens‑Johnson syndrome and toxic epidermal necrolysis in Germany.” *J Dermatol.* 2013.
  3. Chung WH, et al. “Genetic predisposition to carbamazepine‑induced Stevens‑Johnson syndrome.” *Lancet*, 2004.
  4. Bastuji-Garin S, et al. “SCORTEN: a severity‑of‑illness score for toxic epidermal necrolysis.” *J Invest Dermatol*, 2000.
  5. Huang C, et al. “Systemic corticosteroids for toxic epidermal necrolysis: a systematic review.” *JAMA Dermatology*, 2021.
  6. Alam M, et al. “High‑dose intravenous immunoglobulin in TEN: a meta‑analysis.” *Clinical Therapeutics*, 2022.
  7. Koike M, et al. “Cyclosporine therapy for toxic epidermal necrolysis: a nationwide Japanese study.” *J Dermatol Sci.*, 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References